来源：新浪证券-红岸工作室 11月26日，白云山跌0.42%，成交额2.57亿元。两融数据显示，当日白云山获融资买入额2826.26万元， 融资偿还1753.67万元，融资净买入1072.59万元。截至11月26日，白云山融资融券余额合计8.64亿元。 融资方面，白云山当日融资买入2826.26万元。当前融资余额8.63亿元，占流通市值的2.37%，融资余额 超过近一年70%分位水平，处于较高位。 融券方面，白云山11月26日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量4.50万股，融券余额116.59万元，低于近一年30%分位水平，处于低位。 资料显示，广州白云山医药集团股份有限公司位于广东省广州市荔湾区沙面北街45号,香港金钟道89号 力宝中心第2座20楼2005室，成立日期1997年9月1日，上市日期2001年2月6日，公司主营业务涉及中西 成药、化学原料药、天然药物、生物医药、化学原料药中间体的研究开发、制造与销售;西药、中药和 医疗器械的批发、零售和进出口业务;大健康产品的研发、生产与销售;及医疗服务、健康管理、养生养 老等健康产业投资等。主营业务收入构成 ...

Core Viewpoint - The company, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., is set to hold a Q3 2025 performance briefing on November 28, 2025, to discuss its operational results and financial status with investors [2][3]. Group 1: Meeting Details - The performance briefing will take place on November 28, 2025, from 16:00 to 17:00 [4]. - The meeting will be held at the Shanghai Stock Exchange Roadshow Center, accessible via the website: https://roadshow.sseinfo.com/ [4]. - The format of the meeting will be an interactive online session, allowing for real-time communication with investors [3][4]. Group 2: Participation Information - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date and time [5]. - Questions can be submitted by investors from November 21, 2025, to November 27, 2025, through the "Pre-Question Collection" section on the website or via the company's email [5]. - The company will address commonly asked questions during the briefing [5]. Group 3: Attendees - Key personnel attending the briefing include the Executive Director and General Manager, Mr. Li Hong, Independent Director Mr. Huang Longde, Board Secretary Ms. Huang Xuezheng, and Chief Financial Officer Ms. Liu Fei [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於召開2025年第三季度業績說明會的公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年11月20日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 证券代码：600332 证券简称：白云山 公告编号：2025-080 广州白云山医药集团股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、 说明会召 ...

证券代码：600332 证券简称：白云山 公告编号：2025-080 广州白云山医药集团股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 广州白云山医药集团股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更 全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计 划于 2025 年 11 月 28 日（星期五）下午 16:00-17:00 举行 2025 年第 三季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第 会议召开时间：2025 年 11 月 28 日(星期五)下午 16:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资 ...

来源：新浪证券-红岸工作室 11月19日，白云山跌0.94%，成交额1.66亿元。两融数据显示，当日白云山获融资买入额1376.71万元， 融资偿还1548.14万元，融资净买入-171.43万元。截至11月19日，白云山融资融券余额合计8.31亿元。 分红方面，白云山A股上市后累计派现109.06亿元。近三年，累计派现43.59亿元。 机构持仓方面，截止2025年9月30日，白云山十大流通股东中，中国证券金融股份有限公司位居第四大 流通股东，持股4727.80万股，持股数量较上期不变。香港中央结算有限公司位居第五大流通股东，持 股2001.09万股，相比上期减少2043.72万股。华泰柏瑞沪深300ETF（510300）位居第七大流通股东，持 股1214.03万股，相比上期减少49.56万股。易方达沪深300医药ETF（512010）位居第八大流通股东，持 股881.01万股，相比上期减少271.42万股。易方达沪深300ETF（510310）位居第十大流通股东，持股 865.06万股，相比上期减少28.60万股。 融券方面，白云山11月19日融券偿还9400.00股，融券卖出0.00股，按当日收盘价计算， ...

Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. has received a drug registration certificate for Angong Niuhuang Pills from the Vietnamese Ministry of Health, which will allow its subsidiary to expand its market presence in Vietnam [1][3]. Group 1: Drug Information - The drug Angong Niuhuang Pills is a prescription traditional Chinese medicine used for clearing heat and detoxifying, as well as calming and opening the orifices [2]. - The registration number for Angong Niuhuang Pills is VNCT-00006-25, and it is manufactured by Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd. [1]. Group 2: Financial Performance - In 2024, the sales revenue of Angong Niuhuang Pills in China reached RMB 498,242 million, while the sales revenue for Zhongyi Pharmaceutical was RMB 15,611.83 million [2]. - The total research and development investment for the Angong Niuhuang Pills project by Zhongyi Pharmaceutical has reached approximately RMB 3,279.81 million (unaudited) [2]. Group 3: Market Impact - The registration of Angong Niuhuang Pills is expected to enhance the market competitiveness of the company’s products and facilitate the expansion of its business in Vietnam [3]. - The impact of this registration on the company's current performance is not expected to be significant [3].

Key Points - 合富中国's stock will resume trading on November 20 after completing an investigation into unusual trading fluctuations, confirming normal business operations and no undisclosed significant matters [1] - 中金公司 plans to merge with 东兴证券 and 信达证券, leading to a suspension of its A-shares starting November 20 due to uncertainties surrounding the merger [1] - 大为股份 is progressing with the transition from exploration to mining rights for its lithium battery project in Hunan, having received necessary approvals [1] - 燕东微's major shareholders plan to reduce their stakes by up to 2.5% through block trades or centralized bidding from December 11, 2025, to March 11, 2026 [2] - 中水渔业's major shareholder reduced its stake to 5% after selling 258.88 million shares [3] - 韵达股份 reported a slight decline in express service revenue for October 2025, totaling 4.495 billion yuan, a year-on-year decrease of 0.88% [4] - 倍杰特 intends to acquire a 55% stake in 大豪矿业 for 224.8 million yuan [4] - 辰奕智能 plans to acquire a 55% stake in 华泽电子 through cash [4] - 赣粤高速's actual controller will change from the provincial transportation department to the provincial state-owned assets supervision and administration commission [5] - 东软集团 received a notification for a 4.2 billion yuan contract for intelligent cockpit controllers from a major domestic automotive manufacturer [5] - 海正药业's subsidiary plans to invest in a pet prescription food project [5] - 龙利得's controlling shareholder plans to increase its stake by at least 56 million yuan [6] - 新兴装备's shareholders plan to reduce their stakes by up to 3.13% [6] - 普洛药业 plans to repurchase shares worth between 180 million and 360 million yuan [6]

资本运作持续发力，广药资本在管基金认缴规模47亿元，实缴24亿元，将重点投向创新药、高端医疗器械等前沿领域；科 技创新强化核心引擎，布局近20项在研新药，今年新增26个新产品项目；国际拓展迈入新阶段，持续开拓东南亚、中东、南美 市场。 作为本次研讨会的核心亮点之一，广药集团正式揭晓核医疗产业布局及广州白云山稀核健康医药有限公司创新成果。与此 同时，白云山稀核健康与全球医疗科技巨头GE医疗签署战略合作协议，以跨界协同赋能核医疗产业高质量发展。 广药集团党委书记、董事长李小军在欢迎辞中表示，广药集团长期稳健发展与产业链上下游伙伴的精诚协作密不可分。当 前，面对医药健康行业新变化，广药集团正锚定"现代化、数字化、科技化、国际化"战略方向，全力推进"十五五"规划，向 着"再造一个新广药"的目标加速迈进，并取得多方面进展。 （编辑 李家琪 郭之宸） 会上，广药集团联合国家药监局南方医药经济研究所共同发起的"中国创新药研发与产业发展研究报告项目"正式启动。这 一举措将有效整合产业链上下游资源，推动破解创新药研发"卡脖子"难题，助力我国从制药大国向制药强国跨越。 本报讯 （记者王镜茹）11月18日，2025年广州医药集团有 ...

Investment Rating - The report does not explicitly provide an investment rating for the erectile dysfunction (ED) drug industry in China [1]. Core Insights - The Chinese ED drug market is experiencing strong demand and continuous growth, with a shift from traditional medical needs to broader sexual function enhancement [21]. - The market is characterized by increasing competition from domestic generic drugs and new drug developments, which are expected to intensify in the future [21]. - The leading products in the market, such as Sildenafil (Viagra) and Tadalafil (Cialis), have established strong brand recognition and market presence, making it challenging for new entrants to compete [16]. Summary by Sections Current Competitive Landscape - The competitive landscape of the Chinese ED drug market includes several key players with established products such as Sildenafil, Tadalafil, and others, with varying market entry dates and approval statuses [2]. - As of August 2025, the number of approved drug applications and suppliers for various ED drugs is as follows: Sildenafil (92 approvals, 53 suppliers), Tadalafil (172 approvals, 81 suppliers), and others [2]. Differentiation of New Drugs - New drugs like Sumenafil and Tonafadil are positioned with unique advantages, including lower effective doses, safety profiles, and potential for treating pulmonary arterial hypertension [7][9]. - Sumenafils' clinical trials indicate a lower incidence of adverse reactions compared to existing drugs, enhancing its market appeal [9]. Research Progress of PDE5 Inhibitors - The report highlights the ongoing research and development of PDE5 inhibitors, noting that the market is exploring new structural variants and indications beyond traditional uses [11]. - Traditional Chinese medicine is also recognized for its historical role in treating ED, with various herbal ingredients showing PDE5 inhibitory activity [11]. Market Demand and Future Trends - The demand for ED drugs is driven by both medical needs and psychological factors, with a growing acceptance of sexual health discussions in society [21]. - The market is expected to see an increase in competition from domestic companies entering through generics and innovative formulations, leading to a more dynamic market environment [21].

本次获得越南卫生部传统药品管理局颁发的安宫牛黄丸药品注册证书后，该药品将由中一药业授权 TNHH NEWSEEN COAST公司在越南地区销售，有助于中一药业扩展越南市场业务，提升本公司产品 市场竞争力。本次获得安宫牛黄丸药品注册证书，对公司当期业绩无重大影响。 智通财经APP讯，白云山(00874)公布，近日，公司全资子公司广州白云山中一药业有限公司(以下简 称"中一药业")收到越南卫生部传统药品管理局签发的安宫牛黄丸注册证书。 该信息由智通财经网提供 ...